Affinergy

Affinergy is a biotechnology company specializing in site-specific biological delivery and surface modification through its proprietary Interfacial Biomolecule (IFBM) technology. Spun out of Duke University and headquartered in Research Triangle Park, the company develops peptide-based reagents that facilitate the attachment of drugs and cells to medical devices or the capture of biomarkers from complex fluids. Their diverse pipeline includes diagnostic assays for hepcidin, APOL1, and therapeutic drug monitoring, alongside applications in orthopedics and wound healing. Affinergy's platform leverages phage display to identify high-affinity peptides, enabling precision medicine and enhanced performance of medical implants. The company maintains partnerships with major medical device firms and continues to advance its diagnostic and therapeutic programs through federal grants and private investment.